Previous Close | 1.7700 |
Open | 1.7900 |
Bid | 1.8700 x 1200 |
Ask | 1.9000 x 1000 |
Day's Range | 1.6200 - 1.7985 |
52 Week Range | 1.1500 - 10.7900 |
Volume | |
Avg. Volume | 220,379 |
Market Cap | 44.792M |
Beta (5Y Monthly) | 2.41 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.9460 |
Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.25 |
Subscribe to Yahoo Finance Plus to view Fair Value for GRTX
The experimental therapy is designed to treat a side effect of radiation therapy in cancer patients.
Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of avasopasem for SOM will be presented in an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Reported positive topline results from its Phase 2a AESOP trial of avasopasem for chemoradiotherapy-induced esophagitis MALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- G
After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of 2022MALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced its intent to file a New Drug Application (NDA)